ROCKVILLE, Md., Sept. 23, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that a poster highlighting the use of the Company's AutoloGel™ System to effect rapid healing of chronic wounds will be presented at the Symposium on Advanced Wound Care (SAWC) Fall 2010 taking place September 23-25, 2010 in Anaheim, California.
The AutoloGel System is a device for the production of autologous platelet rich plasma ("PRP") gel and is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use on a variety of exuding wounds. Its patent-protected formulation provides physiologically relevant concentrations of PRP that are optimal for wound healing.
The SAWC Fall 2010 posters will be available for viewing on Friday, September 24th from 8:00 a.m. – 4:00 p.m. and during the poster reception occurring from 5:30 p.m. – 6:15 p.m. on Friday. Posters can be viewed through Saturday, September 25, 2010 at Noon. The following poster highlighting Cytomedix's PRP technology will be presented at SAWC Fall 2010:
Presented by Carelyn Fylling, RN, MSN, CWS, CLNC, Cytomedix Clinical Team; Poster Number CR-22.
Commenting on the presentations, Martin P. Rosendale, President and CEO of Cytomedix, Inc., said, "We are delighted to report additional data in support of the use of our AutoloGel System to effect rapid wound healing in chronic wounds in the long-term acute care (LTAC) setting. LTACs are a primary target market for the AutoloGel System as complex and chronic wounds continue to be a growing problem with significant unmet medical need at these facilities. We are delighted to showcase our new data to attendees at the SAWC Fall 2010 meeting as they are the very clinicians and caregivers who treat the patients with these chronic, debilitating wounds."
About the Association for the Advancement of Wound Care
The Association for the Advancement of Wound Care (AAWC) is the preeminent multidisciplinary organization for wound care. The AAWC is a non-profit association, headquartered in the United States. This organization is open to everyone involved in wound care, including clinicians, patients and their lay caregivers, facilities, industry, students, retirees, and others interested in the care of wounds. AAWC was conceived in 1995 to spread awareness by promoting excellence in education, clinical practice, public policy, and research. The AAWC gives its members the opportunity, through numerous Association benefits and activities, to build a collaborative community to facilitate optimal care for those who suffer with wounds. This community encourages an equal partnership among all individuals who are involved in the care of patients.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma and platelet rich plasma ("PRP") in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at .
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Cytomedix, Inc. David Jorden, Executive Board Member Martin Rosendale, CEO Andrew Maslan, CFO (240) 499-2680 Lippert/Heilshorn & Associates Anne Marie Fields (212) 838-3777 firstname.lastname@example.org Bruce Voss (310) 691-7100 email@example.com